NCT06750549Completed
Mobile Application for Patient Engagement and Physician-Directed Remote Management of Heart Failure
Mobile Application for Patient Engagement and Physician-Directed Remote Management of Heart Failure: The ENGAGE-HF Study
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
The ENGAGE-HF mobile application tracks three key features over time: (1) heart failure health status, (2) vital signs (e.g., blood pressure, heart rate) and weight, and (3) the quality of heart failure medication therapy. Helping patients understand how these characteristics interact and change over time may improve their ability to understand and manage heart failure. In this study, the investigators aim to evaluate whether the ENGAGE-HF mobile application, by facilitating the behavior change strategies of self-monitoring and feedback, and a clinician-facing dashboard, improves the optimization of heart failure guideline-directed medical therapies (GDMT) and quality of life. An optional sub-study of cognitive function will invite all eligible participants enrolled in the main study to participate.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 134 (actual)
- First submitted
- 11 Dec 2024
- Start date
- 18 Feb 2025
- Primary completion date
- 1 May 2026
- Lead sponsor
- University of Michigan
- Diseases
- Heart failure
- NCT number
- NCT06750549
What you commit to
- Study type: Interventional
- Participants enrolled: 134
- From 18 Feb 2025 to the primary completion date, 1 May 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inotropic therapy after hospitalization
- History of a prior solid organ transplant or actively listed on heart transplant waiting list
- Currently participating in an investigational device or drug study or having participated in such a study 30 days prior to screening
Other illness
- History of left ventricular assist device implantation
- Cardiac amyloidosis
- Life expectancy estimated less than 6 months related to cardiac or non-cardiac comorbidities as per investigator's judgment
- Any other disorder or condition that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
Other
- Receives dialysis
- Currently pregnant or intends to become pregnant during the study period
- Actively enrolled in hospice or comfort care
- Subject without a compatible smartphone
- Subject not proficient with written and spoken English
- Participant has diminished decision-making capacity
- Admitted to or planned discharge to a skilled nursing facility or rehabilitation facility (acute or subacute)
Who the study is looking for
- Diagnosis of heart failure
- Last left ventricular ejection fraction within 2 years \< 50% based on echocardiogram, MRI, CT, or nuclear perfusion and, if no ejection fraction documented, then clinical documentation of heart failure with reduced ejection fraction
- Currently admitted with upcoming discharge or discharged from hospital within the prior 4 weeks
- At least two eligible heart failure therapies (guideline-recommended BB, RASI, MRA, or SGLT2i) not yet initiated or at \< 50% of target dose at time of enrollment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| U-M Frankel Cardiovascular Center Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
| The Johns Hopkins Hospital Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
| Stanford Cardiovascular Clinic Coordinator of this site? Confirm its status | Stanford | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.